Skip to main content
OpenTrials
Completed

NCT Number: NCT04294654

Vortioxetine in Patients With Depression and Early Dementia

This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression and early dementia

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Major Depressive Disorder Brain Diseases Central Nervous System Diseases Dementia Depressive Disorder Depressive Disorder, Major Mental Disorders Mood Disorders Nervous System Diseases Neurocognitive Disorders

Age range

55 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Marienthali Kliinik, Tallinn, Estonia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient has a primary diagnosis of recurrent Major Depressive Disorder (MDD) with onset before age of 55, diagnosed according to DSM-5®
  • The current major depressive episode (MDE) must be confirmed using the Mini International Neuropsychiatric Interview (MINI).
  • The patient has had the current MDE for <6 months.
  • The patient has a Montgomery and Åsberg Depression Rating Scale (MADRS) total score ≥26 at the Baseline Visit.
  • The diagnosis of onset of dementia has occurred at least 6 months prior to screening and after already being diagnosed with MDD. The diagnosis of dementia must be documented in patient's medical records. When deemed necessary per investigator judgement of patient clinical status and early dementia, the patient must be accompanied by a caregiver to study visits.
  • Patients with dementia associated with vitamin B12 or folate deficiency should not be enrolled.
  • Patients with or without treatment for dementia can be enrolled. For patients on treatment for dementia, there must be no change in treatment during the study and patients must be on stable dose for at least 3 months prior to the Screening Visit.
  • The patient has Mini Mental State Examination (MMSE) total score 20-24, inclusive.

Exclusion criteria

-The patient has any current psychiatric disorder or Axis I disorder (DSM-5® criteria), established as the primary diagnosis, other than MDD, as assessed using the Mini International Neuropsychiatric Interview (MINI) or another diagnostic interview.

Other in- and exclusion criteria may apply

Treatment and study plan

Vortioxetine

Drug

Vortioxetine 5, 10 and 20 mg/day, tablets, orally Patients will receive 5 mg vortioxetine once daily for one week. At visit 3, the dose will be increased to 10 mg/day for all patients. Thereafter the dose may be adjusted to 5, 10 or 20 mg/day.

Primary outcomes

  1. Change in Montgomery and Åsberg Depression Rating Scale (MADRS) total score

    Time frame: from baseline to Week 12

    The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.

Secondary outcomes

  1. Change in Digit-Symbol Substitution Test (DSST) Substitution Test (DSST) score

    Time frame: from baseline to Week 12

    Digit Symbol Substitution Test (DSST) is a cognitive test designed to assess psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-second period. Each correct symbol is counted, and the total score ranges from 0 (less than normal functioning) to 133 (greater than normal functioning)."

  2. Change in Rey Auditory Verbal Learning Test (RAVLT) score

    Time frame: from baseline to Week 12

    Rey Auditory Verbal Learning Task (RAVLT) is a cognitive test designed to assess verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded.

  3. Change in Instrumental Activities of Daily Living (IADL) score

    Time frame: from baseline to Week 12

    The Instrumental Activities of Daily Living (IADL) measures an individual's ability to carry out tasks that are important for daily living and capture functional changes. Scores for each question range from 0 (no assistance needed) to 2 (full assistance needed), and are assessed by informant interview. The scores for IADL (0-14) is the outcome, with higher scores indicating lesser ability to carry out daily living tasks

  4. Change in Clinical Global Impression - Severity (CGI-S) score

    Time frame: from baseline to Week 12

    The Clinical Global Impression severity of illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).

  5. Clinical Global Impression - Improvement (CGI-I) score

    Time frame: at Week 12

    The Clinical Global Impression - global improvement CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

  6. Response defined by decrease in MADRS total score

    Time frame: At Week 12

    Response is defined as a 50% decrease from baseline in MADRS total score

  7. Remission defined by MADRS score

    Time frame: at Week 12

    Remission is defined as MADRS ≤10

  8. Change in Bath Assessment of Subjective Quality of Life in Dementia (BASQID) score

    Time frame: from baseline to Week 12

    The BASQID30 is a clinician rating scale designed to assess subjective quality of life (QoL) in patients with dementia. The BASQID contains 14 core questions, which are scored from 0 to 4, with 4 indicating a better QoL.

Sponsors and collaborators

Lead sponsor

H. Lundbeck A/S

Industry

Collaborators

  • ICON plc

Registry information

Official study title

Interventional, Open-label Study of Flexible Doses of Vortioxetine on Depressive Symptoms in Patients With Major Depressive Disorder and Early Dementia

Acronym: MEMORY

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Mar 4, 2020
Registry last updated
Aug 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.